No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
15 and older
Sex
Any
Study type
Observational
Participants needed
1,150 (estimated)
Sponsor
Centre Hospitalier Universitaire de Nīmes · Other
Who this trial is looking for
This trial is looking for patients aged 15 and older with Multiple Sclerosis who are part of a specific research group. Participants will provide blood samples to help understand the disease activity and progression.
Are You a Good Fit for This Trial?
Rules you outClinically isolated syndromeRadiologically isolated syndromeNeuromyelitis optica spectrum disorder
You may be able to join if
I am at least 15 years old.
I have been diagnosed with Multiple Sclerosis.
I am a participant in the OFSEP-HD cohort.
My Expanded Disability Status Scale score is between 0 - 7.0.
I am enrolled in an OFSEP-HD center and meet the criteria for my disease stage.
You may not be able to join if
I have participated in another study in the past three months.
I am currently under judicial protection.
I refuse to sign consent for the study.
I cannot understand the study information.
I am pregnant or breastfeeding.
I am under 15 years old.
I have a clinically isolated syndrome that does not meet MS criteria.
I have Neuromyelitis optica spectrum disorder.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.
In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* The patient has been correctly informed.
* The patient must have given their informed and signed consent.
* The patient must be insured or beneficiary of a health insurance plan.
* The patient is at least (≥)15 years old.
* The patient has MS according to diagnosis criteria (T…
Inclusion Criteria:
* The patient has been correctly informed.
* The patient must have given their informed and signed consent.
* The patient must be insured or beneficiary of a health insurance plan.
* The patient is at least (≥)15 years old.
* The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:
* Participates to the OFSEP-HD cohort (ancillary study);
* Has a Expanded Disability Status Scale score comprised between 0 - 7.0;
* With or without Disease Modifying Drug;
* For Work Package 3: patients enrolled in any OFSEP-HD centre that meet landmark criteria for an active MS (relapse, or Expanded Disability Status Scale progression, or active MRI) during follow-up;
* For Work Package 4: patients with a stable disease enrolled in OFSEP-HD study in Nîmes or Nantes University Hospitals.
Exclusion Criteria:
* Within the past three months, the patient has participated in another interventional study that may interfere with the results or conclusions of this study.
* The patient is in an exclusion period determined by a previous study.
* The patient is under judicial protection.
* The patient refuses to sign the consent.
* It is impossible to correctly inform the patient (inability to understand the study, language problem).
* The patient is pregnant or breast-feeding.
* The patient is under 15 years old.
* Inability to answer questionnaires.
* Clinically isolated syndrome (CIS) that does not meet the criteria of MS.
* Radiologically isolated syndrome (RIS).
* Patient with Neuromyelitis optica spectrum disorder.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
